Stocks and Investing Stocks and Investing
Mon, June 24, 2024
Fri, June 21, 2024

Matt O"Brien Maintained (TMDX) at Buy and Held Target at $120 on, Jun 21st, 2024


Published on 2024-10-28 12:02:25 - WOPRAI, Matt O'Brien
  Print publication without navigation


Matt O"Brien of Piper Sandler, Maintained "TransMedics Group, Inc." (TMDX) at Buy and Held Target at $120 on, Jun 21st, 2024.

Matt has made no other calls on TMDX in the last 4 months.

There are 6 other peers that have a rating on TMDX. Out of the 6 peers that are also analyzing TMDX, 1 agrees with Matt"s Rating of Hold. Following is the relevant analyst calls for the last 4 months;

Cecilia Furlong of "Morgan Stanley" Maintained at Hold with Increased Target to $95 on, Wednesday, February 28th, 2024

These are the ratings of the 5 analyists that currently disagree with Matt;

Joshua Jennings of "TD Cowen" Maintained at Strong Buy with Increased Target to $175 on, Friday, June 7th, 2024
George Sellers of "Stephens & Co." Initiated at Buy and Held Target at $151 on, Tuesday, June 4th, 2024
Jason Mills of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $117 on, Wednesday, May 1st, 2024
Allen Gong of "JP Morgan" Maintained at Buy with Increased Target to $127 on, Wednesday, May 1st, 2024
Suraj Kalia of "Oppenheimer" Maintained at Buy with Increased Target to $125 on, Wednesday, May 1st, 2024

Contributing Sources